At a glance
- Originator Pfizer
- Class Antibacterials
- Mechanism of Action DNA gyrase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Mycobacterium avium complex infections
Most Recent Events
- 21 Jun 2000 Warner-Lambert has merged with Pfizer
- 27 May 1997 Preclinical development for Mycobacterium avium complex infections in USA (Unknown route)
- 27 May 1997 New profile